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residues are fully active, while lysine substitutions yield a
marginally active protein (12). Arginine-52 appears to be
particularly important in binding TAR. One model proposes
that the imino nitrogens of the guanidino side chain form
specific networks of hydrogen bonds to bridge adjacent
phosphodiesters, linking nucleotides G21 to A22 and A22 to
U23 in the TAR sequence (12). Recent molecular models of
the arginine-rich region of Tat resulting from CD studies
suggest that this basic region is an extended structure (15) or
is unstructured in the absence of RNA (10). Upon binding to
the TAR RNA, however, the peptide may become partially
or fully structured and induce a conformational change in the
RNA (10). Lengthening the peptides to include residues
47-72 enhances the stability but not the affinity of complexes
with TAR (7).
The sequence in TAR that is recognized by the Tat protein
spans nucleotides + 19 to +42, and forms a stable hairpin that
includes a six-nucleotide loop, a trinucleotide bulge, and an
8-base-pair (bp) stem (3, 16, 17). Mutations in the loop are
deleterious for transactivation but have no effect on the
binding of Tat protein or the polybasic peptides (5, 6, 9).
Peptide binding studies show that the trinucleotide bulge and
5 bp adjacent to the bulge are important for Tat binding (8,
11). U23 in the bulge is invariant and is required for nucleoprotein complex formation (5, 6, 18). A recent model of TAR
suggests that the major groove, where the bulge is located, is
similar to that of a B-form double helix and that the Tat
protein binds within this wider major groove (11).

Transcription in the human immunodefiABSTRACT
ciency virus type 1 (HIV-1) retrovirus is regulated by binding
the viral Tat protein (trans-acting transcriptional activator) to
the trans-activation response (TAR) RNA sequence. Here,
vacuum UV circular dichroism (VUV-CD) is used to study the
structure of TAR and its complex with two peptide fragments
that are important for Tat binding to TAR. The VUV-CD
spectrum of TAR is typical of A-form RNA and is minimally
perturbed when bound to either the short or the long Tat
peptide. The CD spectra of the complexes indicate an extended
structure in the argnine-rich region of Tat from amino acid
residue 47 through residue 58 and a short a-helix within the
adjacent 59-72 region. Models of TAR and its peptide complexes are constructed to integrate these spectroscopic results
with current biochemical data. The model suggests that (i) the
arginine-rich 49-58 region is primarily responsible for electrostatic interactions with the phosphates of the RNA, (ii) the
arginine side chains can additionally interact with substituent
groups of the nucleotide bases to confer base recognition in the
complex, (iiW) the recognition of uracil-23 in TAR is facilitated
by the peptide backbone, and (iv) the glutamine-rich face of an
a-helix within the 59-72 region pairs to bases UGG at nucleotide positions 31-33 in the TAR loop and thus provides an
additional motif in the Tat trans-activating protein to recognize
TAR RNA.

Human immunodeficiency virus type 1 (HIV-1) possesses
regulatory genes not found in other retroviral genomes (1).
One of these genes encodes the trans-acting transcriptional
activator (Tat protein), which upon binding to the nucleotide
trans-activation response (TAR) sequence, activates all viral
mRNA transcripts (see ref. 2 for a recent review). The TAR
sequence is present at the 5' end of all HIV-1 mRNAs (3),
suggesting that the binding of Tat to the RNA form of TAR
is an important step in regulating transcription of HIV-1
genes (4-12), although the mechanism of this trans-activation
remains unclear.
Tat is a small protein of 86 residues; however, only the 72
N-terminal amino acids are required for full activity (13).
Mutations within the arginine-rich region from amino acid
residue 47 through residue 58 yield a nonfunctional cytoplasmic Tat protein (14), and short peptides corresponding to this
polybasic region show high affinity for the TAR sequence. A
9-residue peptide containing only arginine residues also binds
TAR with high affinity, while an analogous peptide containing only lysine residues does not (12). Similarly, mutant forms
of Tat in which residues 47-55 have been replaced by arginine

MATERIALS AND METHODS
Synthesis. The RNA was the gift of Gabriele Varani, and
Tat-(47-72)-hexacosapeptide was synthesized as described
(15). Tat-(47-58)-dodecapeptide was synthesized with an
Applied Biosystems 431A synthesizer using "Fast-moc"
chemistry.
VUV-CD Measurements. TAR and TAR-Tat complexes for
vacuum UV circular dichroism (VUV-CD) measurements
were in 10 mM sodium phosphate buffer, pH 7.5/5% (vol/
vol) glycerol/70 mM KF (10). Molar ratios for complex
preparations were 1:1 as monitored by HPLC. Peptide samples were prepared in 10 mM sodium phosphate buffer (pH
7.5), 10 mM NaOH (pH 11), or 80%o (vol/vol) CF3CH20H.
CD spectra were measured in 50-pm path-length cells from
Abbreviations: HIV-1, human immunodeficiency virus type 1; TAR,
trans-activation response element; Tat protein, trans-acting transcriptional activator of HIV-1; C18 HPLC, reverse-phase high-performance
liquid chromatography on C18 columns; VUV, vacuum ultraviolet;
Tat-(47-58), peptide matching Tat sequence 47-58; Tat-(47-72), peptide matching Tat sequence 47-72.
*To whom reprint requests should be addressed.
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320 nm to 178 nm with a VUV-CD spectrophotometer as
described (15). Measurements were performed at 20°C for the
peptides alone and 5°C for TAR and its peptide complexes
(5°C was required to stabilize the complexes). CD spectra are
reported as the difference in extinction coefficient, Ae, per
amide or per nucleotide. The VUV-CD data were analyzed
for secondary structure by the method of Manavalan and
Johnson (19). Purified peptides were analyzed for amino acid
content and concentration on a Beckman 126AA system gold
HPLC amino acid analyzer. The TAR extinction coefficient
is 229,500 M-1-cm-1 at 260 nm per TAR molecule.
Molecular Models of TAR and Its Tat Peptide Complexes.
Initial models for the TAR RNA alone and TAR complexed
with the Tat peptides were constructed by using the INSIGHTII program from Biosym Technologies, similar to previous work (15). Each model was subjected to energy minimization, followed by 1 ps of molecular dynamics at 500 K
after equilibration, and then final energy minimization to a
maximum derivative of 1.0 kcal per step by using the program
DISCOVER from Biosym Technologies, with the AMBER (20)
forcefields, running on a Silicon Graphics 4D30GTX Iris
personal workstation. The structures were optimized in
terms of the internal energies within each molecule and of the
interaction energies between the molecules.

RESULTS AND DISCUSSION
CD Spectrum of TAR RNA. The VUV-CD spectra of
double-stranded DNA and RNA are highly sensitive to the
conformation of the polynucleotide helix. The spectrum of
TAR RNA alone is typical for RNA and is usually associated
with the A-conformation of a polynucleotide helix (Fig. 1).
CD Spectra of the Tat Peptides. The VUV-CD of Tat-(4758) (Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Pro)
at pH 7, pH 11, and in 80% CF3CH2OH is characterized by
a negative band about 198 nm, which is normally attributed
to a random coil structure (Fig. 2). Analysis of these spectra
by the variable selection method gives antiparallel ,B-strand,
,8-turn, and other structure (Table 1). Random coil is not
"other," but is a dynamic system with a propensity for the
4-PT angles associated with 63-strand and (3-turn. These
analyses are typical for a random-coil CD.
The VUV-CD (Fig. 2) and subsequent secondary structure
analyses (Table 1) of the longer Tat-(47-72) peptide (Tyr-

Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Pro-Pro-Gln25a
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FIG. 1. VUV-CD spectra at 5°C of TAR (-), TAR-Tat-(47-58)
complex (--- -), and TAR-Tat-(47-72) complex (- - -) in 10 mM
phosphate buffer, pH 7.5/70 mM KF/5% glycerol, expressed as
M-1 cm-1 per base.
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FIG. 2. VUV-CD spectra of the peptides Tat-(47-58) (Left) and
Tat-(47-72) (Right) in 10 mM phosphate buffer (pH 7.5) (- - -), in
10 mM NaOH (pH 11) (--- ), and in 80%o CF3CH20H (-) as
M-1cm-1 per amide basis. Difference spectra of the TAR-Tat
peptide complexes minus the TAR RNA spectrum (-- -) are represented along with the corresponding peptide as M-l cm-1 per base.

Gly-Ser-Gln-Thr-His-Gln-Val-Ser-Leu-Ser-Lys-Gln) at pH 7
and pH 11 are similar to those of Tat-(47-58) (Fig. 2). In 80%
CF3CH2OH, however, there is a significant increase in a-helix structure, which was not observed with the short peptide
(Table 1). This difference is well illustrated in the emergence
of a broad negative band at long wavelength, a positive band
at 187 nm, and a red shift from 197.5 to 201 nm of the original
negative band. This same CD, showing a higher a-helical
content, was obtained in the presence of 2 mM SDS (results
not shown). This increase in a-helix structure is most likely
located at residues 59-72, since Tat-(47-58) in 80%
CF3CH2OH shows no a-helical structure.
CD Spectrum of the TAR-Tat-(47-58) Complex. The CD of
the complex between TAR and the Tat-(47-58) peptide is
dominated by the RNA (Fig. 1). Moreover, the modest CD
due to the protein contributes only at a wavelength below 240
nm (Fig. 2). The 265-nm band of the RNA is sensitive to base
stacking. The decrease in AE upon forming the complex can
be interpreted as a modification of the base stacking induced
by the binding of Tat-(47-58). Overall, the spectrum, especially the 210-nm band, is still typical of the A-form; thus the
TAR structure is only minimally perturbed in the complex.
A decrease in intensity for the 265-nm band of RNA is
always accompanied by a decrease in intensity for the shorter
wavelength bands, as shown in melting (21) and solvent
perturbation studies (22). In these cases, the first crossover
is virtually unchanged. Alternatively, when an A-form polynucleotide is perturbed toward B-form, the 265-nm band
decreases and the 240-nm band increases in intensity with a
Table 1. Secondary structures predicted by variable selection for
Tat-(47-58) and Tat-(47-72) in phosphate buffer (pH 7), sodium
hydroxide (pH 11), or 80o CF3CH20H
0
Tot
P
T
H
A
Condition
Peptide
0.00 0.17 0.04 0.36 0.43 1.00
Tat-(47-58) pH 7
0.02 0.12 0.05 0.33 0.48 1.00
pH 11
80%o TFE -0.01 0.32 0.03 0.22 0.39 0.%
0.04 0.11 0.01 0.37 0.48 1.00
Tat-(47-72) pH 7
0.06 0.16 0.00 0.31 0.46 1.00
pH 11
80% TFE 0.14 0.15 0.01 0.29 0.41 1.00
TFE, CF3CH20H; H, helix; A, antiparallel,-sheet; P, parallel
(-sheet; T, turn; 0, other structure; Tot, total.
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red shift of the crossover, while the shorter wavelength bands
decrease in intensity (22). This observation is similar to the
effect observed for the TAR complex (Fig. 1), including the
increase in CD to the red-absorbing wavelengths of the
protein bands. This suggests that upon binding, the TAR
RNA assumes a somewhat more B-like character. In any
event, the increases in the magnitude of the CD that we
observe below 240 nm must be due to the protein. The
difference CD shows a maximum at 185 nm and a minimum
at 215 nm (Fig. 2). The negative band at 215 nm cannot be due
to the RNA and matches very well with the CD of a X
structure (21). If we scale the CD of the TAR RNA alone by
the same percentage at all wavelengths to fit the 265-nm band
of the complex (as suggested by solvent perturbations), we
obtain a similar difference spectrum, but with intensities
comparable to that of the uncomplexed peptides (results not
shown). Together, these observations lead to the same interpretation-that Tat-(47-58) adopts an extended structure
upon binding to TAR.
CD of the TAR-Tat-(47-72) Complex. The complex of TAR
with the Tat-(47-72) peptide shows a CD that is very similar
to that obtained for the TAR-Tat-(47-58) complex (Fig. 1). A
clear difference occurs between 235 and 223 nm with a
maximum at 225 nm. The intensity of the negative band near
210 nm is the same in both complexes but is slightly blueshifted to 209 nm in the TAR-Tat-(47-72) complex. The
crossover is blue-shifted from 203.5 to 201 nm. These results
indicate that addition of the C-terminal sequences causes
little additional modification of the TAR structure; therefore,
the primary structural perturbations to TAR are associated
with effects from the 47-58 region of the peptide.
The difference CD spectrum derived from the TAR-Tat(47-72) complex and TAR alone shows two minima at 204 nm
and 215 nm and a maximum at 185 nm (Fig. 2). Again, scaling
the CD of TAR to account for solvent perturbation or B-form
structure does not significantly change the extrema but does
increase the intensity of the bands in the difference spectrum.
The 215-nm band can be attributed to the 13-structure of the
polybasic region that is common between the short and the
long peptide. However, the 204-nm band shows that there is
an a-helix in the Tat peptide complexed to TAR.
The spectra in Fig. 2 are plotted on a per amide basis so that
the bands associated with the (-structure would appear to be
half the intensity in the longer oligomer as observed for the
shorter peptide. The minimum at 204 nm is similar to the
ir-Gro* transition at 205-208 nm of an a-helix (21). For short
a-helices (seven to eight residues long), the characteristic CD
bands are blue-shifted, with the positive band located at
185-187 nm and the negative band at 204-205 nm (23), as
observed here. These results suggest the presence of a short
a-helix, probably no longer than two turns, located at the
C-terminal end of the Tat-(47-72) peptide when complexed to
TAR. The near* transition at 222 nm that is characteristic of
an a-helix is reduced in intensity and broadened to a nondistinct band in the spectra of shorter peptides. In the present
difference spectrum, the 215-nm band overlaps and obscures
the n-?* transition of the short a-helix, but this feature could
account for the difference observed between 223 nm and 235
nm in the CD spectra of the TAR-Tat-(47-58) versus the
TAR-Tat-(47-72) complexes (Fig. 1). The band at 204 nm is
also observed for the Tat-(47-72) peptide alone in 80o
CF3CH2OH and is associated with an increase in a-helix
structure (Table 1). Thus, it appears that the 47-58 region is
an extended structure, while a short a-helix of seven or eight
residues is located in the C-terminal 59-72 region.
Model of TAR RNA. We used the crystal structure of
residues 49-65 from phenylalanine t-RNA, plus the intervening G18 residue, to set guidelines for the structural
features that are important in defining the conformation of the
TAR RNA. The model for the TAR RNA follows the struc-
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tural guidelines set by the t-RNA template (Fig. 3). The
continuity of the A-helix is maintained, and base stacking and
base pairing are maximized as much as possible. The basepaired regions in the TAR model adopt an A-helical conformation, as suggested by the CD. Residues C24 and U25 of the
bulge extend away from the A-helix, while U23 is stacked
between residues A22 and G26. This places a kink in the
A-helix towards the major groove but otherwise leaves the
base stacking and pairing of the stem intact. Interestingly,
U25 appears to form a hydrogen bond to the 2'-hydroxy
group of the ribose and to 0-4 of the base at C24. This
hydrogen-bonding scheme, plus the stacking of U23, may
render the two uracil bases less susceptible to electrophilic
reagents such as diethyl pyrocarbonate (11).
In the model it was logical to pair C30 and G34. Thus, a C-G
base pair separates the UGG (positions 31-33) loop and a
single-base bulge (A35). Residues G32, G33, and G34 are
stacked, while the adenine of A35 forms a triple base pair with
C30-G34.
Model of the TAR-Tat-(47-58) Complex. Weeks and
Crothers (11) suggested that arginine-rich peptides sit in the
major groove of the A-helix of TAR. Earlier studies suggested that this region of the Tat protein is extended (15) and
may be induced to form a specific structure upon binding to
the TAR RNA (10). The current CD results further suggest
that the RNA is only minimally perturbed by binding of this
polybasic region. A model for the complex was constructed
by systematically adding amino acids to the major groove of
the TAR model until the full peptide was generated. In
building this model, we oriented the peptide with the C
terminus towards the loop of the RNA. Studies have shown
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FIG. 3. Comparison of the phenylalanine t-RNA loop and bulge
structure (A) with the TAR RNA model (B). Hydrogen bonds are

drawn as broken lines. The base sequences are labeled along the
ribbon backbone of each structure. The sequence of the TAR RNA
is shown.
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that U23 and at least one additional residue in the bulge of
TAR and the G26&C39 and A27-U38 base pairs are required
for specific binding by the Tat protein (11). In the peptide,
Gln-54 is not crucial for binding to TAR; however, at least
one arginine immediately preceding and at least two arginines
immediately following Gln-54 are necessary. This suggests
that Gln-54 straddles the bulge of the RNA, while one
arginine contacts U23 and two arginines contact the G26-C39
and A27-U38 base pairs. The UCU bulge in the TAR sequence breaks the dyad symmetry of the A-helix. The peptide
thus recognizes the RNA as an asymmetric structure and is
skewed towards the UCU bulge. The role of the bulge in the
TAR sequence, aside from U23, may therefore be primarily
to orient the Tat peptide in the complex. In the final model of
this complex, the peptide and the RNA appear to interact
primarily through electrostatic attraction between the basic
residues of the peptide and the negatively charged phosphates of the RNA (Fig. 4).
The arginines on either side of Gln-54 can also form
hydrogen bonds with specific phosphate oxygens in a fork
arrangement, as suggested by Calnan et al. (12). Unlike the
previously proposed fork structure, however, the arginines in
this model bridge the phosphate to nucleophilic substituents
of the nucleotide bases in the major groove. In particular,
Arg-55 bridges the phosphate between U25 and G26 with N-7
of G26, while Arg-56 bridges the phosphate between G26 and
A27 to the N-7 of A27. This scheme is consistent with the
observations that substituting the G26-C39 base pair with a
U-A base pair or A27-U38 with either U-A or C-G base pairs
diminishes the affinity of Tat for TAR (11).
A similar interaction is observed in this model between
Arg-53 and the critical U23 residue in TAR. First, the base of
U23 is pulled further into the major groove of TAR in this
model of the complex. In this position, the side chain of
Arg-53 bridges the phosphodiester between A22 and U23 and
forms hydrogen bonds to the 0-2 oxygen of U23. However,
arginine side chains do not have the proper hydrogen bonding
potential to recognize the acceptor-donor-acceptor hydrogen bonding pattern of a uracil base. The current model of the
complex presents one possible solution to this problem by
placing the amino nitrogen and carboxyl oxygen of the
peptide backbone of Arg-53 3 A from the extended uracil
base. Thus, the backbone and side-chain functions of Arg-53
can provide the hydrogen bond donor-acceptor-donor pattern necessary to recognize the uracil base which is extended
into the major groove.
Model of the TAR-Tat-(59-72) Complex. The difference CD
of TAR complexed with Tat-(47-72) (Fig. 2) suggests that the
C-terminal 14 amino acids adopt a predominantly a-helical
conformation. The hydrogen bond donor-acceptor functions
of the glutamine side chain are ideally suited for nucleotide
base recognition and binding (24). The three glutamine residues between positions 59 and 66 are in an N+3 pattern,
which defines a glutamine-rich face to an a-helix. In this
arrangement, the glutamines are properly positioned to interact with the bases in the TAR RNA. A search through the
Brookhaven crystallographic protein data base for this N+3
pattern of glutamines located four specific protein structural
motifs. However, only the sequence Gln-Leu-Met-Gln-AlaSer-Gly of hemerythrin was fully an a-helix (25). This N+3
repeat of glutamines was located in the sequence but unfortunately not reported in the crystal structure of the coat
protein from southern bean mosaic virus (26). Thus, although
this peptide sequence may not have a distinct propensity to
form an a-helix, the potential pairing of the glutamines with
the exposed bases of the TAR RNA loop may work synergistically to induce such a structure.
The model of the Tat-(47-72) peptide complexed with TAR
was built by extending the structure of Tat-(47-58) in the TAR
complex with a 14-amino acid a-helix. The initial docking
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and Tat-(50-58) (Lower). The a-helix from Pro-59 to Val-67 is shown
as a cylinder, with the glutamine-rich face oriented towards the loop
of the TAR RNA.

studies showed that these glutamine residues in the a-helix
could easily be positioned to interact with the non-basepaired residues U31, G32, G33, and A35 of TAR. Hydrogen
bonds were thus specified between the peptide and the RNA
residues for Gln-60 to A35, Gln-63 to G33, Gln-66 to U31, and
Gln-72 to G32. These were given thermodynamic weights of
100 kcal/mol for the initial cycles of energy minimization and
molecular dynamics, which were subsequently removed for
the final cycles of molecular simulation. In the final model
(Fig. 4), residues 59-66 remain a-helical, while the remainder
of the C-terminal tail relaxes to form a loop structure. The
additional unstacking of the now peptide-paired RNA bases
is consistent with the observed perturbations to the CD of the
RNA upon binding this longer peptide fragment.
This model is also consistent with the current biochemical
data. RNase digestion studies have shown that the intact Tat
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protein protects not only the bulge but also the loop region of
TAR (27). Furthermore, mutations in the loop region of TAR
have been shown to impede the binding of the longer Tat(47-72) peptide but not the short Tat-(47-58) fragment (28).
Thus, the loop region of the TAR RNA appears to be an
additional site for recognition by the Tat protein.
The bulge and the loop of TAR therefore act in concert to
confer sequence-specific binding by the Tat protein. The
nucleotide sequences present in the loop and the bulge as well
as the spatial relationship between the two are essential for
trans-activation by the Tat protein in HIV-1 (16, 29). Insertion of extra base pairs in the stem that separates the bulge
from the loop decreases the efficiency of trans-activation
(30). Arginine-rich peptides have been shown to have very
high affinities for the TAR sequence, while the C-terminal
59-72 residues do not appear to significantly enhance the
affinity of Tat. However, mutations within this 59-72 region
dramatically decrease Tat function (31). The intermolecular
energy between TAR and residues 49-58 is calculated from
our models to be -710 kcal/mol, with the electrostatic
interactions accounting for fully 80% of the total energy. For
the longer Tat peptide complex, the total intermolecular
energy is -782 kcal/mol, with the four glutamine nucleotide
pairs of our model contributing approximately -20 kcal/mol.
Thus, it appears that residues 47-58 of the Tat protein, and
indeed nearly any arginine-rich peptide, provide the majority
of the binding energy, while the glutamine-rich-face confers
additional specificity to the complex.
Previous studies have described cellular proteins that bind
to the loop and the bulge of the TAR RNA (32-36). Therefore,
a competition between these cellular proteins and Tat could
be an important step in the activation of the virus. A host cell
nuclear protein has been found that binds to the stem loop of
TAR and promotes premature termination of transcripts from
the HIV-1 promoter in vivo (37). Tat, with its higher affinity,
could displace this protein from TAR and thus promote the
elongation of the HIV-1 transcript, which is a Tat function
(38). Another role of region 59-72 could be to facilitate the
trans-activation by stabilizing the Tat-TAR complex, and to
properly position the activating region of Tat.
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